Few numbers in men's health generate more anxiety than a PSA result. A PSA test comes back elevated, and within minutes a man may be googling prostate cancer, mentally preparing for a biopsy, or catastrophizing about treatment side effects. In reality, the PSA test is far more nuanced than a simple pass/fail. Understanding what your result actually means — and what it does not mean — is one of the most important things a man can do for his health.
What Is PSA?
Prostate-specific antigen is a protein produced by cells of the prostate gland — both normal and abnormal ones. It is secreted into seminal fluid to help liquefy semen. A small amount enters the bloodstream and can be measured with a blood test. PSA is organ-specific — it comes only from the prostate — but it is not cancer-specific. Elevated PSA can be caused by BPH, prostatitis, prostate cancer, physical prostate manipulation, ejaculation, and certain medications.
Standard PSA Reference Ranges
| Age Group | Conventional Upper Normal Limit | Notes |
|---|---|---|
| 40–49 | 2.5 ng/mL | Lower threshold applied in younger men |
| 50–59 | 3.5 ng/mL | Most common screening age range |
| 60–69 | 4.5 ng/mL | Prostate volume increases with age |
| 70–79 | 6.5 ng/mL | Higher thresholds reflect expected BPH-related elevation |
These age-specific ranges are intended to increase sensitivity for cancer detection in younger men (where any PSA elevation is less likely to be BPH-related) while reducing unnecessary biopsies in older men whose elevated PSA more likely reflects benign disease. However, these thresholds are guides, not absolute cutoffs — clinical context matters enormously.
PubMed: Catalona WJ et al. - PSA in Early Prostate Cancer DetectionWhat Can Cause an Elevated PSA?
An elevated PSA is not a diagnosis. It is a signal that requires investigation. Common causes include:
- Benign prostatic hyperplasia (BPH): The most common cause of elevated PSA. Larger prostates produce more PSA. A man with a 60cc prostate may have a PSA of 4 to 6 ng/mL entirely from BPH
- Prostatitis: Inflammation of the prostate — bacterial or non-bacterial — can dramatically elevate PSA, sometimes to levels that mimic advanced cancer. PSA typically falls after treatment of prostatitis
- Prostate cancer: Both localized and advanced prostate cancer elevate PSA, though many early cancers produce only modest PSA elevation
- Recent ejaculation: Ejaculation can transiently elevate PSA for 24 to 48 hours. Men should abstain for 48 hours before a PSA test
- Digital rectal exam (DRE): Prostatic massage during DRE can temporarily elevate PSA; PSA should ideally be drawn before the DRE
- Vigorous cycling or horseback riding: Perineal pressure can transiently elevate PSA
- 5-alpha reductase inhibitors (finasteride, dutasteride): These medications suppress PSA by approximately 50%, so a man on these drugs should have his PSA result doubled for interpretation purposes
PSA Density: A More Informative Metric
PSA density (PSAD) is calculated by dividing the PSA level by the prostate volume measured on ultrasound. A PSAD above 0.15 ng/mL/cc is generally considered clinically significant and more suggestive of prostate cancer than a similarly elevated PSA in a man with a very large prostate. PSAD helps distinguish between PSA elevation due to BPH (large prostate, lower PSAD) and PSA elevation due to cancer (any prostate size, higher PSAD).
PSA Velocity: The Rate of Change
PSA velocity is the rate of change in PSA over time, typically expressed in ng/mL per year. A PSA velocity above 0.75 ng/mL per year is considered clinically significant and warrants investigation even if the absolute PSA remains within the normal range. This metric highlights why a single PSA result is less informative than a series of results over time — a trend is more meaningful than a snapshot.
PubMed: Carter HB et al. - PSA Velocity and Prostate Cancer RiskFree vs. Total PSA
PSA circulates in two forms in the blood: free (unbound) PSA and PSA bound to proteins. The percentage of free PSA (%fPSA) is a useful adjunct test when total PSA is in the grey zone of 4 to 10 ng/mL. A lower percentage of free PSA is more associated with prostate cancer, while a higher percentage is more associated with BPH. Generally:
- %fPSA below 10%: Higher cancer probability, biopsy generally recommended
- %fPSA 10–25%: Intermediate zone, clinical judgment required
- %fPSA above 25%: Lower cancer probability, monitoring may be appropriate
What Happens After an Elevated PSA?
An elevated PSA does not automatically lead to a biopsy. The current standard pathway in Canada involves:
- Repeat PSA: Confirm the elevation at least 4 to 6 weeks after the initial test, avoiding confounding factors
- Clinical assessment: DRE, history, IPSS, assessment for prostatitis
- Multiparametric MRI (mpMRI): Now recommended before biopsy in most Canadian urology centres. mpMRI can identify suspicious lesions and guide targeted biopsy, significantly improving cancer detection rates while reducing unnecessary biopsies
- Biopsy: Transperineal or transrectal biopsy if indicated by PSA trend, mpMRI findings, or clinical findings
PSA Is a Tool, Not a Verdict
The most important thing to understand about PSA is that it is the beginning of a clinical conversation, not the end of one. Millions of men have had biopsies prompted by elevated PSA and found no cancer. Millions of others have been spared aggressive treatment through active surveillance protocols that would not exist without PSA monitoring. Used appropriately, in context, with clinical judgment, PSA saves lives. Used in isolation, without context, it generates enormous anxiety for little benefit.
Canadian Screening Recommendations
The Canadian Urological Association recommends individualized PSA screening discussions beginning at age 50 for average-risk men, and earlier (age 40 to 45) for men with a family history of prostate cancer or those of African ancestry. The decision to screen should be made jointly between the patient and physician after a clear discussion of the benefits and limitations of PSA testing.
Canadian Urological Association: Clinical Guidelines